Summary Expression of insulin-like growth factor-I (IGF-I), its receptor and IGF-binding proteins (IGFBPs) by ovarian cancer cells and its mitogenic effect on these cells in vitro, suggest that IGF-I may have a role in regulation of human ovarian cancer. We have recently shown IGFBP-2 to be markedly elevated in malignant ovarian cyst fluid in vivo. To identify the origin of increased IGFBP-2 in these cyst fluids, the gene expression and protein content of IGFBP-2 were investigated in 14 malignant and four benign epithelial ovarian neoplasms. IGFBP-2 mRNA was detected in all ovarian specimens and was 2-to 30-fold higher in malignant than in benign neoplasms. Within the malignant tissues IGFBP-2 mRNA levels correlated with the aggressiveness of the tumour and were higher in invasive tumours than in those with borderline pathology. Southern blot analysis revealed no amplification of IGFBP-2 gene in the DNA samples from ovarian tumours regardless of their nature. IGFBP-2 was the major binding protein in tissue extracts, as measured by both Western ligand blotting and immunoblotting, and was significantly higher in malignant than in benign neoplasms. These findings were further supported by immunohistochemical detection of IGFBP-2 in tumour sections. Our data suggest that increased local production by the tumour in vivo is responsible for the increased IGFBP-2 levels in the cyst fluid bathing the ovarian malignancy. This may represent an autocrine regulatory mechanism for IGF-I proliferative effect of ovarian cancer.
Insulin-like growth factors' (IGFs) effects on cell proliferation are determined by an interplay between the ligands, their receptors as well as multiple IGF-binding proteins (Jones and Clemmons, 1995; LeRoith et al., 1995) . To date, six IGFBPs have been cloned from human tissues designated IGFBP-1 to IGFBP-6 (Shimasaki and Ling, 1991) . All IGFBPs are proteins of 200-300 amino acids with a molecular weight of 24-43 kDa and are synthesised ubiquitously. Beyond their capacity as carriers, IGFBPs regulate IGF impact on cell proliferation by modulating its access to the IGF receptors (Jones and Clemmons, 1995) . Therefore, increased IGF action in aberrant growth can occur secondary to alterations in IGFBP levels or function induced by the target cell. For example, proteolysis of IGFBP-3 by prostate-specific antigen (PSA) is suggested to increase availability of IGF-I to prostate tumour cells, which produce PSA (Cohen et al., 1992; Kanety et al., 1993) . Alternatively, increased presence of IGFBP-3 in colon cancer cell culture has been shown to promote IGF-I effect through anchoring of IGFBP-3 on the cell membrane, which facilitates IGF-I access to its receptor (Singh et al., 1994) .
We have recently reported IGFBP-2 to be significantly higher in cyst fluid from invasive malignant than from benign epithelial ovarian neoplasms (Karasik et al., 1994) . Serum IGFBP-2 levels were also higher in women with invasive malignancy than in women with benign neoplasms. Moreover, IGFBP-2 was higher in cyst fluids than in the corresponding sera, implying local production of this protein. Tissue localisation of IGFBP-2 by immunohistochemistry Paraffin-embedded tissue sections (4 Mrm-thick) were deparaffinised, hydrated through xylene-graded alcohol series, treated with 3% hydrogen peroxide (H202) to neutralise endogenous peroxidase, washed in Tris buffer (pH 7.6) and incubated with rabbit antiserum against bovine (1:200) or rabbit antiserum against human for 30 min at room temperature. Sections were washed extensively and then incubated with biotinylated anti-rabbit IgG for 30 min, followed by incubation for an additional 30 min with streptavidin-conjugated horseradish peroxidase using a commercial kit (Dako, Cappinteria, CA, USA) according to the manufacturer's directions. The antibodybound peroxidase was visualised with 3'aminoethylcarbazole (AEC). Slides were counterstained in Mayer's haematoxylin before microscopic examination. Control sections were stained in parallel with normal rabbit IgG or with buffer alone. Neither control exhibited detectable staining.
Statistical analysis
Comparison of IGFPB-2 mRNA levels between groups was calculated using the two-tailed Wilcoxon rank sum test.
Results
IGFBPs in primary ovarian neoplasms IGFBPs in protein extracts prepared from primary benign and malignant epithelial ovarian neoplasms were evaluated by Western ligand blotting and immunoblotting. As depicted in Figure 1 , the 32 kDa IGFBP-2 was the major IGFBP in tissue extracts of all ovarian neoplasms. It was significantly higher in malignant (Figure 1 , five right lanes) than in benign neoplasms (Figure 1 , two left lanes). Low levels of 24, 29, 40 and 43 kDa IGFBPs were also observed in some of the extracts obtained from malignant neoplasms (Figure 1 ).
Immunohistochemical localisation of IGFBP-2
To ascertain that IGFBP-2 is localised in epithelial neoplastic ovarian tissues, specimens were evaluated by immunohistochemical staining with IGFBP-2-specific antibody (Figure 2 ). The sections in Figure 2 were taken from a benign serous papillary cystadenoma (Figure 2a ) and a poorly differentiated serous cystadenocarcinoma (Figure 2b) . The 
IGFBP-2 gene expression
To evaluate further the origin of the high IGFBP-2 levels observed in ovarian malignant neoplasms, RNA isolated from benign (Ben, n = 4), borderline malignant (B, n = 3), invasive primary (I, n = 5) and metastatic (M, n = 6) ovarian neoplasms was assayed for IGFBP-2 gene expression. The 1.4 kb IGFBP-2 transcript was detected in all ovarian specimens and was significantly higher (2-to 30-fold) in invasive malignant compared with benign neoplasms (Figure 3 ). Within the malignant tissues, mean IGFBP-2 mRNA levels correlated with the aggressiveness of the tumour and were higher (P= 0.01) in invasive tumours than in all others (Figure 4) (Kanety et al., 1993) , lung cancer (Reeve et al, 1990) and others. Our previous finding of high levels of IGFBP-2 in cyst fluid and serum from patients with ovarian malignant neoplasms (Karasik et al., 1994 ) is in line with these reports. Tumourderived cell lines including cells from ovarian origin express and produce IGFBP-2 (Yee et al., 1991; Reeve et al., 1992; Hofmann et al., 1994) . Ovarian cancer tissues were also shown to express preferentially IGFBP-2 (Krywicki et al., 1993 ). In the current study we have supplied evidence that the source of the increase in IGFBP-2 levels in body fluids of patients with ovarian malignancy is overproduction of IGFBP-2 by the tumour itself. Moreover, in the more invasive tumours IGFBP-2 mRNA was more abundant.
The biological significance of these findings is less obvious. IGFBPs have three major functions that are essential in regulating the biological effects of IGFs (Jones and Clemmons, 1995) : they serve as a storage pool and determine the metabolic fate of IGFs; they may inhibit IGFs' effect by competing with the IGF receptors; and they may potentiate IGFs' effect by targeting them to specific cells and tissues. Addition of the various IGFBPs in vitro to different transformed cells resulted in both suppressive or facilitatory effects on IGF actions. Transfection experiments aimed at constitutively increasing the production of IGFBPs also resulted in conflicting effects. In BALB/c3T3 cells expression of recombinant IGFBP-3 resulted in growth inhibition of these cells (Cohen et al., 1993) , whereas in MCF-7 breast carcinoma cells IGFBP-3 overexpression increased cell proliferation upon IGF-I treatment (Chen et al., 1994) . IGFBP-2 has been shown to inhibit IGFstimulated DNA synthesis and mitogenesis in fibroblasts (Schwander et al., 1989) and human lung carcinoma cell lines in culture (Reeve et al., 1993) . In contrast, IGF-I effects were increased by addition of purified IGFBP-2 to microvascular endothelial cells (Bar et al., 1989) , aortic smooth muscle cells (Bourner et al., 1992) and breast carcinoma cells (Chen et al., 1994) . These contradictory results may be explained by multiple factors that are present or absent in the specific experimental system. Proteases which proteolyse IGFBPs and reduce their affinity to IGFs (Conover et al., 1993) as well as other modifications (phosphorylation) (Jones et al., 1991) may be responsible for the observed differences. These points underline the caution that should be exercised in interpreting the biological role of increased IGFBP-2 production by the ovarian neoplasms. Nevertheless, this demonstration of increased IGFBP-2 production in situ and especially the correlation between the mRNA overexpression and the invasiveness of the tumour suggest that IGFBP-2 may stimulate cell growth or invasiveness. Under this speculation, increased production of IGFBP-2 may represent an autocrine mechanism by which the invasive tumour perpetuates and augments its own growth and development. Of interest is the observation that metastases contain low IGFBP-2 mRNA in comparison with the ovarian tumour source. This may result potentially from a paracrine effect of ovarian tissue that may induce IGFBP-2 expression. Oestrogens may be a potential mediator of such an effect, as oestradiol has been shown to induce IGFBP-2 expression in breast cancer cells in correlation with positive oestrogen receptor content (Yee et al., 1991) . Moreover, we have described a correlation between the E2 and IGFBP-2 content in cyst fluids from ovarian tumours (Karasik et al., 1994) .
Gene amplification is one of the mechanisms leading to overexpression of proteins in malignancy. We have excluded IGFBP-2 gene amplification as the mechanism for the increased expression but did not pursue other possibilities. One clue for an investigative direction comes from a recent study (Kutoh et al., 1993) which identified a silencer domain of the rat IGFBP-2 gene. This domain contains target sequences termed RCE, for retinoblastoma gene product, a well-characterised tumour-suppressor gene. This finding suggests a possible interplay between tumour-suppressor genes altered in malignancy which may lead to increased IGFBP-2 expression and, in turn, may increase tumour invasiveness through augmenting IGF mitogenic action.
The consistent correlation between tumour invasiveness and IGFBP-2 mRNA overexpression in ovarian neoplasms calls for a verification and follow-up in a larger sample of patients, as it can be a potential prognostic factor used to predict tumour aggressiveness.
